Clinical Trial

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-06
notable Trial sites expanded: 5 -> 11 locations 2026-08-06
notable Primary completion pushed: 2039-12-01 -> 2041-12-01 2026-08-06
minor Completion pushed: 2039-12-01 -> 2041-12-01 2026-08-06
Trial Details
NCT Number NCT06116110
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma, Central Nervous System Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)
Enrollment 150 participants
Start Date 2024-05-15
Primary Completion 2041-12-01 (estimated)
Study Completion 2041-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05